BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
BIOTRICITY INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.05+0.00 (+8.70%)
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
BIOTRICITY INC. revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Technology Fees [Member] | $14.44M | $12.59M | $11.25M | $8.80M | $5.90M | $2.75M | 90.3% | +14.7% |
| Device Sales [Member] | $1.56M | $1.20M | $814.23K | $837.03K | $995.88K | $635.90K | 9.7% | +29.9% |
| Service Related and Other Revenue [Member] | – | – | – | – | $750.00K | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biotricity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.